CEO of Theravance Inc. (THRX, Financial) Rick E Winningham sells 252,300 shares of THRX on 02/28/2011 at an average price of $22.24 a share.
Theravance Inc. has a market cap of $1.69 billion; its shares were traded at around $22.78 with and P/S ratio of 69.6.
Hedge Fund Gurus that owns THRX: Seth Klarman of The Baupost Group, Julian Robertson of Tiger Management, John Griffin of Blue Ridge Capital, Wilbur Ross of Invesco Private Capital, Inc., Jim Simons of Renaissance Technologies LLC, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns THRX: David Swensen of Yale University, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
For the complete insider trading history of THRX, click here.
Theravance Inc. has a market cap of $1.69 billion; its shares were traded at around $22.78 with and P/S ratio of 69.6.
Hedge Fund Gurus that owns THRX: Seth Klarman of The Baupost Group, Julian Robertson of Tiger Management, John Griffin of Blue Ridge Capital, Wilbur Ross of Invesco Private Capital, Inc., Jim Simons of Renaissance Technologies LLC, Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns THRX: David Swensen of Yale University, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
CEO Recent Trades:
- Sell: CEO Rick E Winningham sold 266,400 shares of THRX stock on 02/23/2011 at the average price of 21.35. Rick E Winningham owns at least 556,273 shares after this. The price of the stock has increased by 6.7% since.
CFO Recent Trades:
- Sell: Sr VP, CFO Michael W Aguiar sold 10,000 shares of THRX stock on 12/03/2010 at the average price of 26.51. Michael W Aguiar owns at least 109,601 shares after this. The price of the stock has decreased by 14.07% since.
Directors and Officers Recent Trades:
- Buy: 10% Owner Plc Glaxosmithkline bought 152,278 shares of THRX stock on 02/18/2011 at the average price of 23.7. Plc Glaxosmithkline owns at least 5,902,278 shares after this. The price of the stock has decreased by 3.88% since.
- Buy: 10% Owner Plc Glaxosmithkline bought 5,750,000 shares of THRX stock on 11/29/2010 at the average price of 22.5. Plc Glaxosmithkline owns at least 5,750,000 shares after this. The price of the stock has increased by 1.24% since.
- Sell: SVP, Research & Early Clin Dev Mathai Mammen sold 3,701 shares of THRX stock on 02/18/2011 at the average price of 23.12. Mathai Mammen owns at least 249,382 shares after this. The price of the stock has decreased by 1.47% since.
- Sell: Director William D Young sold 5,376 shares of THRX stock on 02/18/2011 at the average price of 23.22. William D Young owns at least 28,753 shares after this. The price of the stock has decreased by 1.89% since.
- Sell: Director William D Young sold 5,377 shares of THRX stock on 12/10/2010 at the average price of 26.64. William D Young owns at least 23,377 shares after this. The price of the stock has decreased by 14.49% since.
For the complete insider trading history of THRX, click here.
